Physicochemical Properties
| Molecular Formula | C20H21CLFN5O3S |
| Molecular Weight | 465.92884516716 |
| Exact Mass | 465.103 |
| CAS # | 1450595-86-4 |
| PubChem CID | 71711862 |
| Appearance | White to off-white solid powder |
| LogP | 3.3 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 6 |
| Heavy Atom Count | 31 |
| Complexity | 699 |
| Defined Atom Stereocenter Count | 2 |
| SMILES | ClC1C=C(C(=CC=1O[C@H]1CCCC[C@@H]1C1=CC=NN1C)F)S(NC1C=CN=CN=1)(=O)=O |
| InChi Key | OJKONCJPCULNOW-DYVFJYSZSA-N |
| InChi Code | InChI=1S/C20H21ClFN5O3S/c1-27-16(6-9-25-27)13-4-2-3-5-17(13)30-18-11-15(22)19(10-14(18)21)31(28,29)26-20-7-8-23-12-24-20/h6-13,17H,2-5H2,1H3,(H,23,24,26)/t13-,17+/m1/s1 |
| Chemical Name | 5-chloro-2-fluoro-4-[(1S,2R)-2-(2-methylpyrazol-3-yl)cyclohexyl]oxy-N-pyrimidin-4-ylbenzenesulfonamide |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | hNav1.7 22.8 nM (IC50) mNav1.7 59.4 nM (IC50) |
| ln Vivo | A positive toxicological profile is shown by DS-1971a[1]. In mice with partial sciatic nerve ligation (PSL), DS-1971a (0.1–1 mg/kg; po) exhibits dose-dependently reduced heat hyperalgesia[1]. |
| Animal Protocol |
Animal/Disease Models: Male Slc:ddY mice (PSL model)[1] Doses: 0.1, 0.3, and 1 mg/kg Route of Administration: Po Experimental Results: A significant dose-dependent suppression of thermal hyperalgesiain 0.3 and 1 mg/kg administered groups. The ED50 of DS-1971a at the peak efficacy was 0.32 mg/kg. |
| References |
[1]. Discovery of DS-1971a, a Potent, Selective NaV1.7 Inhibitor [published online ahead of print, 2020 May 26]. J Med Chem. 2020;10.1021/acs.jmedchem.0c00259. |
Solubility Data
| Solubility (In Vitro) | DMSO: 100 mg/mL (214.62 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.37 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.37 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (5.37 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1462 mL | 10.7312 mL | 21.4625 mL | |
| 5 mM | 0.4292 mL | 2.1462 mL | 4.2925 mL | |
| 10 mM | 0.2146 mL | 1.0731 mL | 2.1462 mL |